TARS Quote, Financials, Valuation and Earnings

Celcuity, Inc. has a net margin of -5.52% compared to Tarsus Pharmaceuticals, Inc.'s net margin of --. Tarsus Pharmaceuticals, Inc.'s return on equity of -21.04% beat Celcuity, Inc.'s return on equity of -158.5%.

Tarsus Pharmaceuticals, Inc. has a consensus price target of $94.38, signalling upside risk potential of 24.97%. On the other hand Celcuity, Inc. has an analysts' consensus of $116.70 which suggests that it could grow by 4.47%. Given that Tarsus Pharmaceuticals, Inc. has higher upside potential than Celcuity, Inc., analysts believe Tarsus Pharmaceuticals, Inc. is more attractive than Celcuity, Inc..

Tarsus Pharmaceuticals, Inc. has a beta of 0.550, which suggesting that the stock is 45.037% less volatile than S&P 500. In comparison Celcuity, Inc. has a beta of 0.382, suggesting its less volatile than the S&P 500 by 61.833%.

Tarsus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celcuity, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tarsus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Celcuity, Inc. pays out -- of its earnings as a dividend.

Tarsus Pharmaceuticals, Inc. quarterly revenues are $151.7M, which are larger than Celcuity, Inc. quarterly revenues of --. Tarsus Pharmaceuticals, Inc.'s net income of -$8.4M is higher than Celcuity, Inc.'s net income of -$43.8M. Notably, Tarsus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Celcuity, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tarsus Pharmaceuticals, Inc. is 6.99x versus -- for Celcuity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Mirum Pharmaceuticals, Inc. has a net margin of -5.52% compared to Tarsus Pharmaceuticals, Inc.'s net margin of -3.85%. Tarsus Pharmaceuticals, Inc.'s return on equity of -21.04% beat Mirum Pharmaceuticals, Inc.'s return on equity of -8.84%.

Tarsus Pharmaceuticals, Inc. has a consensus price target of $94.38, signalling upside risk potential of 24.97%. On the other hand Mirum Pharmaceuticals, Inc. has an analysts' consensus of $122.36 which suggests that it could grow by 32.59%. Given that Mirum Pharmaceuticals, Inc. has higher upside potential than Tarsus Pharmaceuticals, Inc., analysts believe Mirum Pharmaceuticals, Inc. is more attractive than Tarsus Pharmaceuticals, Inc..

Tarsus Pharmaceuticals, Inc. has a beta of 0.550, which suggesting that the stock is 45.037% less volatile than S&P 500. In comparison Mirum Pharmaceuticals, Inc. has a beta of 0.520, suggesting its less volatile than the S&P 500 by 48.002%.

Tarsus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tarsus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Mirum Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Tarsus Pharmaceuticals, Inc. quarterly revenues are $151.7M, which are larger than Mirum Pharmaceuticals, Inc. quarterly revenues of $148.9M. Tarsus Pharmaceuticals, Inc.'s net income of -$8.4M is lower than Mirum Pharmaceuticals, Inc.'s net income of -$5.7M. Notably, Tarsus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Mirum Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tarsus Pharmaceuticals, Inc. is 6.99x versus 9.17x for Mirum Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Precigen, Inc. has a net margin of -5.52% compared to Tarsus Pharmaceuticals, Inc.'s net margin of -5008.35%. Tarsus Pharmaceuticals, Inc.'s return on equity of -21.04% beat Precigen, Inc.'s return on equity of -711.28%.

Tarsus Pharmaceuticals, Inc. has a consensus price target of $94.38, signalling upside risk potential of 24.97%. On the other hand Precigen, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 124.27%. Given that Precigen, Inc. has higher upside potential than Tarsus Pharmaceuticals, Inc., analysts believe Precigen, Inc. is more attractive than Tarsus Pharmaceuticals, Inc..

Tarsus Pharmaceuticals, Inc. has a beta of 0.550, which suggesting that the stock is 45.037% less volatile than S&P 500. In comparison Precigen, Inc. has a beta of 1.097, suggesting its more volatile than the S&P 500 by 9.675%.

Tarsus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precigen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tarsus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Precigen, Inc. pays out -- of its earnings as a dividend.

Tarsus Pharmaceuticals, Inc. quarterly revenues are $151.7M, which are larger than Precigen, Inc. quarterly revenues of $2.9M. Tarsus Pharmaceuticals, Inc.'s net income of -$8.4M is higher than Precigen, Inc.'s net income of -$146.3M. Notably, Tarsus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Precigen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tarsus Pharmaceuticals, Inc. is 6.99x versus 178.77x for Precigen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Summit Therapeutics, Inc. has a net margin of -5.52% compared to Tarsus Pharmaceuticals, Inc.'s net margin of --. Tarsus Pharmaceuticals, Inc.'s return on equity of -21.04% beat Summit Therapeutics, Inc.'s return on equity of -292.79%.

Tarsus Pharmaceuticals, Inc. has a consensus price target of $94.38, signalling upside risk potential of 24.97%. On the other hand Summit Therapeutics, Inc. has an analysts' consensus of $31.72 which suggests that it could grow by 91.13%. Given that Summit Therapeutics, Inc. has higher upside potential than Tarsus Pharmaceuticals, Inc., analysts believe Summit Therapeutics, Inc. is more attractive than Tarsus Pharmaceuticals, Inc..

Tarsus Pharmaceuticals, Inc. has a beta of 0.550, which suggesting that the stock is 45.037% less volatile than S&P 500. In comparison Summit Therapeutics, Inc. has a beta of -1.429, suggesting its less volatile than the S&P 500 by 242.925%.

Tarsus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Summit Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tarsus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Summit Therapeutics, Inc. pays out -- of its earnings as a dividend.

Tarsus Pharmaceuticals, Inc. quarterly revenues are $151.7M, which are larger than Summit Therapeutics, Inc. quarterly revenues of --. Tarsus Pharmaceuticals, Inc.'s net income of -$8.4M is higher than Summit Therapeutics, Inc.'s net income of -$219.2M. Notably, Tarsus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Summit Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tarsus Pharmaceuticals, Inc. is 6.99x versus 21,812.02x for Summit Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.